1. Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives Nat Rev Cardiol. 2017 Mar;14(3):156-170
2. McAloon CJ, Boylan LM, Hamborg T, Stallard N, Osman F, Lim PB, Hayat SA. The changing face of cardiovascular disease 2000-2012: An analysis of the world health organization global health estimates data. Int J Cardiol. 2016 Dec 1;224:256-264
3. 厚生労働省 平成 27 年厚労省人口動態統計
4. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med, 340, 115-126
5. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011 Nov 29; 58(23):2432-46.
6. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013 Oct 1; 82(4):E266-355.
7. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011 Dec 6; 58(24):e123-210.
8. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 Jan; 45 Suppl S:S5-67.
9. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI; Vascular inflammation and repair : implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057-66
10.Born GV, Cross MJ. The aggregation of blood platelets. J Physiol. 168: 178-195(1963)
11.Clowes AW, Reidy MA, Clowes MM. Kinetics of cellar proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 49:327-333(1983)
12.Wu B, Mottola G, Schaller M, Upchurch GR Jr, Conte MS. Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. Mol Aspects Med. 2017 Dec;58: 72-82.
13.Ozaki Y, Violaris AG, Serruys PW. New stent technologies. Prog Cardiovasc Dis. 1996 Sep-Oct; 39(2):129-40.
14.Fredman G, Serhan CN. Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J. 2011 Jul 15;437(2):185-97
15.Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol. 2005 Apr 1;174(7):4345-55.
16.Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011 Oct 12; 111(10):5922-43
17.Serhan C. N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005 Dec; 6(12):1191-7.
18. Serhan C. N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007;25: 101–137
19.Serhan C. N., Chiang N., Van Dyke T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008 May;8(5):349-61.
20. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology.Nature. 2014 Jun 5; 510(7503): 92–101.
21.Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009 Oct 29;461(7268):1287-91
22.Xia H, Chen L, Liu H, Sun Z, Yang W, Yang Y, Cui S, Li S, Wang Y, Song L, Abdelgawad AF, Shang Y, Yao S. Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype. Sci Rep. 2017 Mar 7;7(1):99
23.Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, Serhan CN, Bonventre JV. Resolvin D Series and Protectin D1 mitigate acute kidney injury. J Immunol. 2006 Nov 1;177(9):5902-11
24. Gobbetti T, Dalli J, Colas RA, Federici Canova D, Bonnet D, Alric L, Vergnolle N, Deraison C, Hansen TV, Serhan CN, Perretti M. Protectin D1n-3 DPA and Resolvin D5n-3 DPA are effectors of intestinal protection. Proc Natl Acad Sci U.S.A. 2017 Apr 11;114(15):3963-3968
25. Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, Kadowaki A, Ohto T, Nakanishi H, Taguchi R, Nakaya T, Murakami M, Yoneda Y, Arai H, Kawaoka Y, Penninger JM, Arita M, Imai Y. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell. 2013 Mar 28;153(1):112-25
26. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014 Mar 20;40(3):315-27
27.Dangi B, Obeng M, Nauroth JM, Chung G, Bailey-Hall E, Hallenbeck T, Arterburn LM. Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6) Biochem Pharmacol. 2010 Jan 15;79(2):251-60.
28.Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27
29.Clària J, López-Vicario C, Rius B, Titos E. Pro-resolving actions of SPM in adipose tissue biology. Mol Aspects Med. 2017 Dec;58:83-92.
30.Wu B, Mottola G, Chatterjee A, Lance KD, Chen M, Siguenza IO, Desai TA, Conte MS. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J Vasc Surg. 2017 Jan;65(1):207-217
31.Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004 Jun 1; 101(22):8491-6
32.Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 2007 Jun 14;447(7146):869-74.
33.Chen P, Véricel E, Lagarde M, Guichardant M. Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. FASEB J. 2011 Jan;25(1):382-8
34.Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, Baer T, Yang R, Colgan SP, Petasis NA. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol. 2006 Feb 1;176(3):1848-59.
35.Chen P, Fenet B, Michaud S, Tomczyk N, Véricel E, Lagarde M, Guichardant M. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 2009 Nov 3;583(21):3478-84.
36.Chen P, Véricel E, Lagarde M, Guichardant M. Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. FASEB J. 2011 Jan;25(1):382-8
37.血管生物学事典 日本血管生物医学会編集 佐藤靖史、森田育男、 高倉伸幸、小室一成 監修、朝倉書店 2011 年
38.D. B. Landry, L. L. Couper, S. R. Bryant, V. Lindner Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 1997 Oct; 151(4): 1085–1095.
39.Libby P. Inflammation in atherosclerosis. Nature. 2002 Dec 19-26; 420(6917): 868-74.
40.Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther. 2001 Nov;8(21):1635-42.
41.Saito T, Hasegawa Y, Ishigaki Y, Yamada T, Gao J, Imai J, Uno K, Kaneko K, Ogihara T, Shimosawa T, Asano T, Fujita T, Oka Y, Katagiri H. Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation. Cardiovasc Res. 2013 Jan 1;97(1):106-14.
42.Miyahara, T., Runge, S., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J.M. , Serhan CN, Conte MS. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013; 4: 1–13
43.Akagi, D., Chen, M., Toy, R., Chatterjee, A., Conte, M.S. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015; 29: 2504–2513
44.Petri, M.H., Laguna-Fernandez, A., Tseng, C.N., Hedin, U., Perretti, M., Back, M. Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int J Cardiol. 2015; 20: 370–372
45.カッツング薬理学 原書 10 版 柳沢輝行・飯野正光・丸山敬・三 澤美和 監訳 丸善株式会社 2009 年
46.図解・実験動物技術集 I 14 ページ、株式会社アドスリー 日本 実験動物技術者協会 図解・実験動物技術集編集委員会 2005 年 東京 丸善株式会社出版事業部
47.Keyes KT, Ye Y, Lin Y, Zhang C, Perez-Polo JR, Gjorstrup P, Birnbaum Y. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H153-64
48.Zhao Q, Wu J, Lin Z, Hua Q, Zhang W, Ye L, Wu G, Du J, Xia J, Chu M, Hu X. Resolvin D1 Alleviates the Lung Ischemia Reperfusion Injury via Complement, Immunoglobulin, TLR4, and Inflammatory Factors in Rats. Inflammation. 2016 Aug;39(4):1319-33
49.Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 1997 Oct; 151(4):1085-95.
50.Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004 Mar 1;61(4):671-82
51.Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002 Feb 5;105(5):633-8.
52.Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N., Sakonjo H, Makino H, Kaneda Y, Ogihara T, Morishita R. Activation of the NF-kB and Ik B system in smooth muscle cells after rat arterial injury. Gene Ther. 2003 Feb 10(4) 356-64
53.Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003 Oct;170(2):191-203.
54.Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012 Mar 16;110(6):875-88.
論文の公開元へ
